EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Surveillance for factor VIII inhibitor development in the Canadian hemophilia A population following the widespread introduction of recombinant factor VIII replacement therapy



Surveillance for factor VIII inhibitor development in the Canadian hemophilia A population following the widespread introduction of recombinant factor VIII replacement therapy



Transfusion Science 19(2): 139-148, June



In the Fall of 1994 the majority of Canadian Hemophilia A (Factor VIII (F.VII) deficiency) patients who were receiving replacement therapy were converted to Recombinant Factor VIII (rF.VIII) from plasma derived products. This decision was taken and funded by the Canadian Blood Agency following the advice of the Association of Hemophilia Centre Directors of Canada (AHCDC) who considered this to be the safest replacement therapy available. Although it was the considered opinion of the AHCDC that there was no evidence available to support the theoretical concern that rF.VIII may prove more immunogenic than plasma derived products, patient follow up included intensive surveillance of all patients converted for this complication. A central reference laboratory was established and plasma specimens obtained before and 6-12 months following conversion to rF.VIII were referred for evaluation for inhibitor development by the classical Bethesda Assay. By consensus of the referring centers a Bethesda Unit (BU)/activity of 0.5 or greater was considered to be clinically significant. No increase in the incidence of inhibitor development has been recorded in 478 patients followed for one year after conversion. This pattern has not changed in 339 of these patients followed for a further year. Of interest was the finding by the reference laboratory that 8.0% of patients had BU activity of 0.5 or greater before conversion to rF.VIII. Many of these individuals lost this activity after conversion to rF.VIII as did others who appeared to have developed inhibitory activity during the first year of follow up but became inhibitor free in the second year of therapy. Overall, the incidence of true inhibitor development, i.e. negative pre-/positive post-conversion to rF.VIII, in this population of Hemophilia A patients was 2-3% over 2 years. This is similar to the incidence in patients treated with plasma derived products. These data emphasize the need for rigorous baseline evaluation in such investigations and the heterogeneity of the inhibitor response as assessed by in vitro assay. It was concluded that, although no attempt was made to correlate these in vitro data with clinical observations including F.VIII recovery and survival, the use of rF.VIII in hemophiliacs previously treated with plasma derived products was not associated with an increase in F.VIII inhibitor development.

(PDF emailed within 0-6 h: $19.90)

Accession: 009495905

Download citation: RISBibTeXText

PMID: 10187039

DOI: 10.1016/S0955-3886(98)00024-1



Related references

A prospective surveillance study of factor VIII inhibitor development in the Canadian haemophilia A population following the switch to a recombinant factor VIII product formulated with sucrose. Haemophilia 14(2): 281-286, 2008

Factor VIII inhibitors development following introduction of B-domain-deleted recombinant factor VIII in four hemophilia A previously treated patients. Journal of Thrombosis and Haemostasis 1(11): 2450-2451, 2003

Rapid acquisition of immunologic tolerance to factor VIII and disappearance of anti-factor VIII IgG4 after prophylactic therapy in a hemophilia A patient with high-titer factor VIII inhibitor. Journal of Pediatric Hematology/Oncology 37(4): E220-E222, 2015

Factor viii inhibitor following surgery for epidural hemorrhage in hemophilia successful therapy with a concentrate containing factor ii factor viii factor ix and factor x. Journal Of Pediatrics: 356-357, 1976

"Antihemophilic factor is not the only answer for all factor VIII deficiencies." Case report of odontogenic infection in a patient with hemophilia A, complicated by factor VIII inhibitors, and managed by transfusion of antihemophilic factor and factor VIII inhibitor bypass activity. Indian Journal of Dentistry 7(3): 149-152, 2016

Detection of carriers of hemophilia a activities of factor viii pro coagulant factor viii inhibitor neutralizing material anti human factor viii antibody neutralizing material factor viii related antigen and von willebrand factor in plasma of female carriers. Journal of the Nagoya Medical Association 29(1): 47-60, 1978

Hemophilic patients with an inhibitor to factor VIII treated with high dose factor VIII concentrate. Results of a collaborative study for the evaluation of factor VIII inhibitor titer, recovery and half life of infused factor VIII. Nouvelle Revue Francaise D'hematologie 28(2): 85-89, 1986

Recombinant factor VIII. An introduction to recombinant DNA technology and the first results published in the replacement treatment of hemophilia A. Medicina Clinica 103(15): 591-595, 1994

Factor VIII inhibitors in patients with hemophilia A: epidemiology of inhibitor development and induction of immune tolerance for factor VIII. Seminars in Thrombosis and Hemostasis 21(4): 382-389, 1995

Prostate carcinoma associated spontaneous factor VIII:C inhibitor hemophilia. Successful therapy of severe hemorrhagic complication with porcine factor VIII in a 75-year-old patient. Medizinische Klinik 92(4): 241-245, 1997

Incidence of factor VIII inhibitor development in previously untreated hemophilia A patients after exposure to a double viral inactivated factor VIII concentrate. Annals of Hematology 78(SUPPL 1): A10, 1999

Human recombinant DNA-derived antihemophilic factor (factor VIII) in the treatment of hemophilia A. recombinant Factor VIII Study Group. New England Journal of Medicine 323(26): 1800-1805, 1990

Immunological and hemostatic studies of hemophilia a and von willebrands disease part 1 antigenicity to factor viii inhibitor and rabbit anti serum against human factor viii in the plasma of hemophilia a. Journal of the Nagoya Medical Association 29(1): 22-33, 1978

Cost analysis of plasma-derived factor VIII/von Willebrand factor versus recombinant factor VIII for treatment of previously untreated patients with severe hemophilia A in the United States. Journal of Medical Economics 21(8): 762-769, 2018

Studies on factor viii during coagulation process part 1 levels of factor viii pro coagulant factor viii related antigen and von willebrand factor in plasma and serum of normal children patients with hemophilia a or von willebrands disease. Journal of the Nagoya Medical Association 29(1): 61-68, 1978